p.119 抽出テキスト

967. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:819–837. https://doi. org/10.1161/CIRCRESAHA.117.310982 968. Mori H, Kogaki S, Ishida H, Yoshikawa T, Shindo T, Inuzuka R, et al. Outcomes of restrictive cardiomyopathy in Japanese children–a retrospective cohort study. Circ J 2022;86:1943–1949. https://doi.org/10.1253/circj.CJ-21-0706 969. Rivenes SM, Kearney DL, Smith EO, Towbin JA, Denfield SW. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 2000;102: 876–882. https://doi.org/10.1161/01.CIR.102.8.876 970. Mogensen J, Arbustini E. Restrictive cardiomyopathy. Curr Opin Cardiol 2009;24: 214–220. https://doi.org/10.1097/HCO.0b013e32832a1d2e 971. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000;101:2490–2496. https://doi.org/10.1161/01.CIR.101.21.2490 972. Anderson HN, Cetta F, Driscoll DJ, Olson TM, Ackerman MJ, Johnson JN. Idiopathic restrictive cardiomyopathy in children and young adults. Am J Cardiol 2018;121: 1266–1270. https://doi.org/10.1016/j.amjcard.2018.01.045 973. Walsh MA, Grenier MA, Jefferies JL, Towbin JA, Lorts A, Czosek RJ. Conduction abnormalities in pediatric patients with restrictive cardiomyopathy. Circ Heart Fail 2012;5:267–273. https://doi.org/10.1161/CIRCHEARTFAILURE.111.964395 974. Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 2020;22:1076–1096. https://doi.org/10.1002/ejhf.1960 975. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008;105:2812–2817. https://doi.org/10.1073/pnas.0712309105 976. Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30. https://doi.org/10.1186/ 1750-1172-5-30 977. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 2018;123:416–427. https://doi.org/10.1016/j.ymgme.2018.02.014 978. Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016; 89:44–54. https://doi.org/10.1111/cge.12613 979. Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017;91:284–293. https://doi.org/10.1016/j.kint.2016.10.004 980. Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, et al. Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol 2021;77:922–936. https://doi.org/10.1016/j.jacc.2020.12.024 981. Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet 2019;96:107–117. https://doi.org/10.1111/cge.13546 982. Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE. Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis 2006;48:844–850. https://doi.org/10. 1053/j.ajkd.2006.05.034 983. Politei J, Frabasil J, Durand C, Di Pietrantonio S, Fernandez A, Alberton V, et al. Incidental finding of cornea verticillata or lamellar inclusions in kidney biopsy: measurement of lyso-Gb3 in plasma defines between Fabry disease and drug-induced phospholipidosis. Biochim Biophys Acta Mol Basis Dis 2021;1867:165985. https://doi.org/10. 1016/j.bbadis.2020.165985 984. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet 1985;21: 493–506. https://doi.org/10.1002/ajmg.1320210312 985. Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 2011;25:161–179. https://doi.org/10.1016/j. beem.2010.09.002 986. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013;381: 333–342. https://doi.org/10.1016/S0140-6736(12)61023-X 987. Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann NY Acad Sci 2010; 1214:99–121. https://doi.org/10.1111/j.1749-6632.2010.05790.x 988. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126: 746–759. https://doi.org/10.1542/peds.2009-3207 989. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465–468. https://doi.org/10.1038/ng772 990. Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P, et al. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol 2007;100:736–741. https://doi.org/10.1016/j.amjcard.2007.03.093 991. Limongelli G, Sarkozy A, Pacileo G, Calabro P, Digilio MC, Maddaloni V, et al. Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. Am J Med Genet A 2008;146A:620–628. https://doi.org/10. 1002/ajmg.a.32206 992. Gripp KW, Morse LA, Axelrad M, Chatfield KC, Chidekel A, Dobyns W, et al. Costello syndrome: clinical phenotype, genotype, and management guidelines. Am J Med Genet A 2019;179:1725–1744. https://doi.org/10.1002/ajmg.a.61270 993. Gripp KW, Hopkins E, Sol-Church K, Stabley DL, Axelrad ME, Doyle D, et al. Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C. Am J Med Genet A 2011;155A:706–716. https://doi.org/10.1002/ajmg.a.33884 994. Pierpont ME, Magoulas PL, Adi S, Kavamura MI, Neri G, Noonan J, et al. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2014;134:e1149–e1162. https://doi.org/10.1542/peds.2013-3189 995. Allanson JE, Anneren G, Aoki Y, Armour CM, Bondeson ML, Cave H, et al. Cardio-facio-cutaneous syndrome: does genotype predict phenotype? Am J Med Genet C Semin Med Genet 2011;157C:129–135. https://doi.org/10.1002/ajmg.c.30295 996. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006;38:294–296. https://doi.org/10.1038/ng1749 997. Calcagni G, Gagliostro G, Limongelli G, Unolt M, De Luca E, Digilio MC, et al. Atypical cardiac defects in patients with RASopathies: updated data on CARNET study. Birth Defects Res 2020;112:725–731. https://doi.org/10.1002/bdr2.1670 998. Hickey EJ, Mehta R, Elmi M, Asoh K, McCrindle BW, Williams WG, et al. Survival implications: hypertrophic cardiomyopathy in Noonan syndrome. Congenit Heart Dis 2011;6:41–47. https://doi.org/10.1111/j.1747-0803.2010.00465.x 999. Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J 2012;164:442–448. https://doi.org/10. 1016/j.ahj.2012.04.018 1000. Prendiville TW, Gauvreau K, Tworog-Dube E, Patkin L, Kucherlapati RS, Roberts AE, et al. Cardiovascular disease in Noonan syndrome. Arch Dis Child 2014;99:629–634. https://doi.org/10.1136/archdischild-2013-305047 1001. Cerrato F, Pacileo G, Limongelli G, Gagliardi MG, Santoro G, Digilio MC, et al. A standard echocardiographic and tissue Doppler study of morphological and functional findings in children with hypertrophic cardiomyopathy compared to those with left ventricular hypertrophy in the setting of Noonan and LEOPARD syndromes. Cardiol Young 2008;18:575–580. https://doi.org/10.1017/S104795110800320X 1002. Colquitt JL, Noonan JA. Cardiac findings in Noonan syndrome on long-term followup. Congenit Heart Dis 2014;9:144–150. https://doi.org/10.1111/chd.12102 1003. Ishizawa A, Oho S, Dodo H, Katori T, Homma SI. Cardiovascular abnormalities in Noonan syndrome: the clinical findings and treatments. Acta Paediatr Jpn 1996;38: 84–90. https://doi.org/10.1111/j.1442-200X.1996.tb03444.x 1004. Bertola DR, Castro MAA, Yamamoto GL, Honjo RS, Ceroni JR, Buscarilli MM, et al. Phenotype-genotype analysis of 242 individuals with RASopathies: 18-year experience of a tertiary center in Brazil. Am J Med Genet C Semin Med Genet 2020;184: 896–911. https://doi.org/10.1002/ajmg.c.31851 1005. Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007;115:773–781. https://doi.org/10.1161/CIRCULATIONAHA.106.621185 1006. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999;34:1813–1822. https://doi.org/10.1016/S0735- 1097(99)00421-0 1007. Jackson G, Anand IS, Oram S. Asymmetric septal hypertrophy and propranolol treatment in a case of Ullrich–Noonan syndrome. Br Heart J 1979;42:611–614. https://doi. org/10.1136/hrt.42.5.611 1008. Chen H, Li X, Liu X, Wang J, Zhang Z, Wu J, et al. Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort. Orphanet J Rare Dis 2019;14:29. https://doi.org/10.1186/ s13023-019-1010-z 1009. McCallen LM, Ameduri RK, Denfield SW, Dodd DA, Everitt MD, Johnson JN, et al. Cardiac transplantation in children with Noonan syndrome. Pediatr Transplant 2019;23:e13535. https://doi.org/10.1111/petr.13535 1010. Chen S, Chen L, Jiang Y, Xu H, Sun Y, Shi H, et al. Early outcomes of septal myectomy for obstructive hypertrophic cardiomyopathy in children with Noonan syndrome. Semin Thorac Cardiovasc Surg 2022;34:655–665. https://doi.org/10.1053/j.semtcvs. 2021.07.027 1011. Schleihauf J, Cleuziou J, Pabst von Ohain J, Meierhofer C, Stern H, Shehu N, et al. Clinical long-term outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in infants. Eur J Cardiothorac Surg 2018;53:538–544. https://doi.org/10. 1093/ejcts/ezx369 1012. Holzmann J, Tibby SM, Rosenthal E, Qureshi S, Morgan G, Krasemann T. Results of balloon pulmonary valvoplasty in children with Noonan’s syndrome. Cardiol Young 2018;28:647–652. https://doi.org/10.1017/S1047951117002827 1013. Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA. The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child 2007;92:128–132. https://doi. org/10.1136/adc.2006.104547

ESC Guidelines                                                                                                                                                                                          3621

Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026